Development of nitrile-based peptidic inhibitors of cysteine cathepsins

Current Topics in Medicinal Chemistry

Volumn 10, Issue 3, 2010, Pages 294-322

  Frizler, Maxim ^a   Stirnberg, Marit ^a   Sisay, Mihiret Tekeste ^a   Gütschow, Michael ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

Cathepsin; Covalent modifier; Cysteine protease; Lysosomotropic property; Osteoporosis; Peptide nitrile; Peptidomimetic; Protease inhibitor; Thioimidate

Indexed keywords

BALICATIB; BORTEZOMIB; CATHEPSIN B; CATHEPSIN B INHIBITOR; CATHEPSIN K; CATHEPSIN K INHIBITOR; CATHEPSIN L; CATHEPSIN S; CLAVULANIC ACID; CLOPIDOGREL; CYANAMIDE; CYCLOSERINE; CYSTEINE PROTEINASE INHIBITOR; DIPEPTIDYL PEPTIDASE I; DIPEPTIDYL PEPTIDASE IV INHIBITOR; NILVADIPINE; NITRILE; ODANACATIB; OMEPRAZOLE; PEPTIDOMIMETIC AGENT; RIVASTIGMINE; TELAPREVIR; TETRAHYDROLIPSTATIN;

DRUG DESIGN; DRUG DEVELOPMENT; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; OSTEOPOROSIS; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; CATALYTIC DOMAIN; CATHEPSINS; DRUG DESIGN; HUMANS; NITRILES; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77949483288     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802610790725452     Document Type: Review

References (200)

1. López-Otín, C.; Overall, C. M. Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol., 2002, 3, 509-519.
2. Rawlings, N. D.; Morton, F. R.; Barrett, A. J. MEROPS: the peptide database. Nucleic Acids Res., 2006, 34, D270-D272.
3. Polgar, L. Catalytic mechanisms of cysteine peptidase. In: Barrett, A. J.; Rawlings, N. D.; Woessner, J. F. Eds., Handbook of Proteolytic Enzymes, Elsevier, London, 2004, 1072-1079.
4. Brix, K.; Dunkhorst, A.; Mayer, K.; Jordans, S. Cysteine cathepsins: cellular roadmap to different functions. Biochimie., 2008, 90, 194-207.
5. Mort, J. S.; Buttle, D. J. Cathepsin B. Int. J. Biochem. Cell Biol., 1997, 29, 715-720.
6. Ishidoh, K.; Kominami, E. Processing and activation of lysosomal proteinases. Biol. Chem., 2002, 383, 1827-1831.
7. Nishimura, Y.; Kawabata, T.; Kato, K. Identification of latent procathepsins B and L in microsomal lumen: characterization of enzymatic activation and proteolytic processing in vitro. Arch. Biochem. Biophys., 1988, 261, 64-71.
8. Kominami, E.; Tsukahara, T.; Hara, K.; Katunuma, N. Biosyntheses and processing of lysosomal cysteine proteinases in rat macrophages. FEBS Lett., 1988, 231, 225-228.
9. Ménard, R.; Carmona, E.; Takebe, S.; Dufour, E.; Plouffe, C.; Mason, P.; Mort, J. S. Autocatalytic processing of recombinant human procathepsin L. Contribution of both intermolecular and unimolecular events in the processing of procathepsin L in vitro. J. Biol. Chem., 1998, 273, 4478-4484.
10. Mach, L.; Mort, J. S.; Glössl, J. Maturation of human procathepsin B. Proenzyme activation and proteolytic processing of the precursor to the mature proteinase, in vitro, are primarily unimolecular processes. J. Biol. Chem., 1994, 269, 13030-13035.
11. Kawabata, T.; Nishimura, Y.; Higaki, M.; Kato, K. Purification and processing of rat liver procathepsin B. J. Biochem., 1993, 113, 389-394.
12. Dahl, S. W.; Halkier, T.; Lauritzen, C.; Dolenc, I.; Pedersen, J.; Turk, V.; Turk B. Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsins L and S but not by autocatalytic processing. Biochemistry, 2001, 40, 1671-1678.
13. Dolenc, I.; Turk, B.; Pungercic, G.; Ritonja, A.; Turk, V. Oligomeric structure and substrate induced inhibition of human cathepsin C. J. Biol. Chem., 1995, 270, 21626-21631.
14. 2. Biochem. J., 2007, 401, 645-650.
15. Drenth, J.; Jansonius, J. N.; Koekoek, R.; Swen, H. M.; Wolthers, B. G. Structure of papain. Nature, 1968, 218, 929-932.
16. Musil, D.; Zucić, D.; Turk, D.; Engh, R. A.; Mayr, I.; Huber, R.; Popovic, T.; Turk, V.; Towatari, T.; Katunuma, N.; Bode, W. The Refined 2.15 Å X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. EMBO J., 1991, 10, 2321-2330.
17. Olsen, J. G.; Kadziola, A.; Lauritzen, C.; Pedersen, J.; Larsen, S.; Dahl, S. W. Tetrameric dipeptidyl peptidase I directs substrate specificity by use of the residual pro-part domain. FEBS Lett., 2001, 506, 201-206.
18. Turk, D.; Janjić, V.; Stern, I.; Podobnik, M.; Lamba, D.; Dahl, S. W.; Lauritzen, C.; Pedersen, J.; Turk, V.; Turk, B. Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases. EMBO J., 2001, 20, 6570-6582.
19. Somoza, J. R.; Palmer, J. T.; Ho, J. D. The crystal structure of human cathepsin F and its implications for the development of novel immunomodulators. J. Mol. Biol., 2002, 322, 559-568.
20. Gunčar, G.; Podobnik, M.; Pungerčar, J.; Štrukelj, B.; Turk, V.; Turk, D. Crystal structure of porcine cathepsin H determined at 2.1 Å resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function. Structure, 1998, 6, 51-61.
21. Fujishima, A.; Imai, Y.; Nomura, T.; Fujisawa, Y.; Yamamoto, Y.; Sugawara, T. The crystal structure of human cathepsin L complexed with E-64. FEBS Lett., 1997, 407, 47-50.
22. Gunčar, G.; Pungerčar, G.; Klemenčič , I.; Turk, V.; Turk, D. Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. EMBO J., 1999, 18, 793-803.
23. McGrath, M. E.; Klaus, J. L.; Barnes, M. G.; Brömme, D. Crystal structure of human cathepsin K complexed with a potent inhibitor. Nat. Struct. Biol., 1997, 4, 105-109.
24. Zhao, B.; Janson, C. A.; Amegadzie, B. Y.; D'Alessio, K.; Griffin, C.; Hanning, C. R.; Jones, C.; Kurdyla, J.; McQueney, M.; Qiu, X.; Smith, W. W.; Abdel-Meguid, S. S. Crystal structure of human osteoclast cathepsin K complex with E-64. Nat. Struct. Biol., 1997, 4, 109-111.
25. McGrath, M. E.; Palmer, J. T.; Brömme, D.; Somoza, J. R. Crystal Structure of human cathepsin S. Protein Sci., 1998, 7, 1294-1302.
26. Turkenburg, J. P.; Lamers, M. B.; Brzozowski, A. M.; Wright, L. M.; Hubbard, R. E.; Sturt, S. L.; Williams, D. H. Structure of a Cys25→Ser mutant of human cathepsin S. Acta Crystallogr. D Biol. Crystallogr., 2002, 58, 451-455.
27. Pauly, T. A.; Sulea, T.; Ammirati, M.; Sivaraman, J.; Danley, D. E.; Griffor, M. C.; Kamath, A. V.; Wang, I. K.; Laird, E. R.; Seddon, A. P.; Ménard, R.; Cygler, M.; Rath, V. L. Specificity determinants of human cathepsin S revealed by crystal structures of complexes. Biochemistry, 2003, 42, 3203-3213.
28. Somoza, J. R.; Zhan, H.; Bowman, K. K.; Yu, L.; Mortara, K. D.; Palmer, J. T.; Clark, J. M.; McGrath, M. E. Crystal structure of human cathepsin V. Biochemistry, 2000, 39, 12543-12551.
29. Gunčar, G.; Klemenčič, I.; Turk, B.; Turk, V.; Karaoglanovic-Carmona, A.; Juliano, L.; Turk, D. Crystal structure of cathepsin X: a flip-flop of the ring of His23 allows carboxy-monopeptidase and carboxy-dipeptidase activity of the protease. Structure, 2000, 8, 305-313.
30. Turk, D.; Gunčar, G. Lysosomal cysteine proteases (cathepsins): promising drug targets. Acta Crystallogr. D Biol. Crystallogr., 2003, 59, 203-213.
31. Cygler, M.; Sivaraman, J.; Grochulski, P.; Coulombe, R.; Storer, A. C.; Mort, J. S. Structure of procathepsin B. Model for inhibition of cysteine protease activity by the proregion. Structure, 1996, 4, 405-416.
32. Turk, D.; Podobnik, M.; Kuhelj, R.; Dolinar, M.; Turk, V. Crystal structures of human procathepsin B at 3.2 and 3.3 Angstroms resolution reveal an interaction motif between a papain-like cysteine protease and its Propeptide. FEBS Lett., 1996, 384, 211-214.
33. Podobnik, M.; Kuhelj, R.; Turk, V.; Turk, D. Crystal structure of the wild-type human procathepsin B at 2.5 Å resolution reveals the native active site of a papain-like cysteine protease zymogen. J. Mol. Biol., 1997, 271, 774-788.
34. Coulombe, R.; Grochulski, P.; Sivaraman, J.; Ménard, R.; Mort, J. S.; Cygler, M. Structure of human procathepsin L reveals the molecular basis of inhibition by the prosegment. EMBO J., 1996, 15, 5492-5503.
35. Sivaraman, J.; Lalumière, M.; Ménard, R.; Cygler, M. Crystal structure of wild-type human procathepsin K. Protein Sci., 1999, 8, 283-290.
36. Turk, V.; Turk, B.; Turk, D. Lysosomal cysteine proteases: facts and opportunities. EMBO J., 2001, 20, 4629-4633.
37. LaLonde, J. M.; Zhao, B.; Janson, C. A.; D'Alessio, K. J.; McQueney, M. S.; Orsini, M. J.; Debouck, C. M.; Smith, W. W. The crystal structure of human procathepsin K. Biochemistry, 1999, 38, 862-369.
38. Sivaraman, J.; Nägler, D. K.; Zhang, R.; Ménard, R.; Cygler, M. Crystal structure of human procathepsin X: a cysteine protease with the proregion covalently linked to the active site cysteine. J. Mol. Biol., 2000, 295, 939-951.
39. Cygler, M.; Mort, J. S. Proregion structure of members of the papain superfamily. Mode of inhibition of enzymatic activity. Biochimie, 1997, 79, 645-652.
40. Turk, B.; Turk, D.; Turk, V. Lysosomal cysteine proteases: more than scavengers. Biochim. Biophys. Acta, 2000, 1477, 98-111.
41. Guay, J.; Falgueyret, J. P.; Ducret, A.; Percival, M. D.; Mancini, J. A. Potency and selectivity of inhibition of cathepsin K, L and S by their respective propeptides. Eur. J. Biochem., 2000, 267, 6311-6318.
42. Nägler, D. K.; Zhang, R.; Tam, W.; Sulea, T.; Purisima, E. O.; Ménard, R: Human cathepsin X: a cysteine protease with unique carboxypeptidase activity. Biochemistry, 1999, 38, 12648-12654.
43. Klemenčič, I.; Carmona, A. K.; Cezari, M. H.; Juliano, M. A.; Juliano, L.; Gunčar, G.; Turk, D.; Križaj, I.; Turk, V.; Turk, B. Biochemical characterization of human cathepsin X revealed that the enzyme is an exopeptidase, acting as carboxymonopeptidase or carboxydipeptidase. Eur. J. Biochem., 2000, 267, 5404-5412.
44. Chapman, H. A.; Riese, R. J.; Shi G. P. Emerging roles for cysteine proteases in human biology. Annu. Rev. Physiol., 1997, 59, 63-88.
45. Pisoni, R. L.; Acker, T. L.; Lisowski, K. M.; Lemons, R. M.; Thoene, J. G. A cysteine-specific lysosomal transport system provides a major route for the delivery of thiol to human fibroblast lysosomes: possible role in supporting lysosomal proteolysis. J. Cell Biol., 1990, 110, 327-335.
46. Turk, V.; Stoka, V.; Turk, D. Cystatins: biochemical and structural properties, and medical relevance. Front. Biosci., 2008, 13, 5406-5420.
47. Deussing, J.; Roth, W.; Saftig, P.; Peters, C.; Ploegh, H. L.; Villadangos, J. A. Cathepsins B and D are dispensable for major histocompatibility complex class II-mediated antigen presentation. Proc. Natl. Acad. Sci. USA, 1998, 95, 4516-4521.
48. Nakagawa, T.; Roth, W.; Wong, P.; Nelson, A.; Farr, A.; Deussing, J.; Villadangos, J. A.; Ploegh, H.; Peters, C.; Rudensky, A. Y. Cathepsin L: Critical role in Ii degradation and CD4 T cell selection in the thymus. Science, 1998, 280, 394-395.
49. Saftig, P.; Hunziker, E.; Wehmeyer, O.; Jones, S.; Boyde, A.; Rommerskirch, W.; Moritz, J. D.; Schu, P.; von Figura, K. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. USA, 1998, 95, 13453-13458.
50. Shi, G. P.; Villadangos, J. A.; Dranoff, G.; Small, C.; Gu, L.; Haley, K. J.; Riese, R.; Ploegh, H. L.; Chapman, H. A. Cathepsin S is required for normal MHC class II peptide loading and germinal center development. Immunity, 1999, 10, 197-206.
51. Pham, C. T.; Ley, T. J. Dipeptidyl peptidase I is required for the processing and activation of granzymes A and B in vivo. Proc. Natl. Acad. Sci. USA, 1999, 96, 8627-8632.
52. Roth, W.; Deussing, J.; Botchkarev, V. A.; Pauly-Evers, M.; Saftig, P.; Hafner, A.; Schmidt, P.; Schmahl, W.; Scherer, J.; Anton-Lamprecht, I.; von Figura, K.; Paus, R.; Peters, C. Cathepsin L deficiency as molecular defect of furless: hyperproliferation of keratinocytes and pertubation of hair follicle cycling. FASEB J. 2000, 14, 2075-2086.
53. Nägler, D. K.; Ménard, R. Family C1 cysteine proteases: biological diversity or redundancy? Biol. Chem., 2003, 384, 837-843.
54. Kirschke, H.; Wiederanders, B.; Brömme, D.; Rinne, A. Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem. J., 1989, 264, 467-473.
55. Brömme, D.; Li, Z.; Barnes, M.; Mehler, E. Human cathepsin V functional expression, tissue distribution, electrostatic surface potential, enzymatic characterization, and chromosomal localization. Biochemistry, 1999, 38, 2377-2385.
56. Brömme, D.; Okamoto, K.; Wang, B. B.; Biroc, S. Human cathepsin O2, a matrix protein degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J. Biol. Chem., 1996, 271, 2126-2132.
57. Brix, K.; Lemansky, P.; Herzog, V. Evidence for extracellularly acting cathepsins mediating thyroid hormone liberation in thyroid epithelial cells. Endocrinology, 1996, 137, 1963-1974.
58. Andrews, N. W. Regulated secretion of conventional lysosomes. Trends Cell. Biol. 2000, 10, 316-321.
59. Reinheckel, T.; Deussing, J.; Roth, W.; Peters, C. Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. Biol. Chem., 2001, 382, 735-741.
60. Büth, H.; Buttigieg, P. L.; Ostafe, R.; Rehders, M.; Dannenmann, S. R.; Schaschke, N.; Stark, H. -J.; Boukamp, P.; Brix, K. Cathepsin B is essential for regeneration of scratch-wounded normal human epidermal keratinocytes. Eur. J. Cell Biol., 2007, 86, 747-761.
61. Obermajer, N.; Jevnikar, Z.; Doljak, B.; Kos, J. Role of cysteine cathepsins in matrix degradation and cell signalling. Connect. Tissue Res., 2008, 49, 193-196.
62. Guicciardi, M. E.; Deussing, J.; Miyoshi, H.; Bronk, S. F.; Svingen, P. A.; Peters, C.; Kaufmann, S. H.; Gores, G. J. Cathepsin B contributes to TNF-α-mediated hepatocyte apoptosis by promoting mitochondrial release of cytochrome c. J. Clin. Invest., 2000, 106, 1127-1137.
63. Cirman, T.; Oresić, K.; Mazovec, G. D.; Turk, V.; Reed, J. C.; Myers, R. M.; Salvesen, G. S.; Turk, B. Selective disruption of lysosomes in HeLa cells triggers apoptosis mediated by cleavage of Bid by multiple papain-like lysosomal cathepsins. J. Biol. Chem., 2004, 279, 3578-3587.
64. Stoka, V.; Turk, V.; Turk, B. Lysosomal cysteine cathepsins: signaling pathways in apoptosis. Biol. Chem., 2007, 388, 555-360.
65. Conus, S.; Simon, H. U. Cathepsins: key modulators of cell death and inflammatory responses. Biochem. Pharmacol., 2008, 76, 1374-1382.
66. Halangk, W.; Lerch, M. M.; Brandt-Nedelev, B.; Roth, W.; Ruthenbuerger, M.; Reinheckel, T.; Domschke, W.; Lippert, H.; Peters, C.; Deussing, J. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J. Clin. Invest., 2000, 106, 773-781.
67. Friedrichs, B.; Tepel, C.; Reinheckel, T.; Deussing, J.; von Figura, K.; Herzog, V.; Peters, C.; Saftig, P.; Brix, K. Thyroid functions of mouse cathepsins B, K, and L. J. Clin. Invest., 2003, 111, 1733-1745.
68. Felbor, U.; Kessler, B.; Mothes, W.; Goebel, H. H.; Ploegh, H. L.; Bronson, R. T.; Olsen, B. R. Neuronal loss and brain atrophy in mice lacking cathepsins B and L. Proc. Natl. Acad. Sci. USA, 2002, 99, 7883-7888.
69. Brömme, D.; Okamoto, K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary. Molecular cloning, sequencing and tissue distribution. Biol. Chem. Hoppe Seyler, 1995, 376, 379-384.
70. Inaoka, T.; Bilbe, B.; Ishibashi, O.; Tezuka, K.; Kumegawa, M.; Kokubo, T. Molecular cloning of human cDNA for cathepsin K: novel cysteine proteinase predominantly expressed in bone. Biochem. Biophys. Res. Comm., 1995, 206, 89-96.
71. Bühling, F; Gerber, A.; Häckel, C.; Krüger, S.; Köhnlein, T.; Brömme, D.; Reinhold, D.; Ansorge, S.; Welte, T. Expression of cathepsin K in lung epithelial cells. Am. J. Respir. Cell Mol. Biol., 1999, 20, 612-619.
72. Tepel, C.; Brömme, D.; Herzog, V.; Brix, K. Cathepsin K in thyroid epithelial cells: sequence, localization and possible function in extracellular proteolysis of thyroglobulin. J. Cell Sci., 2000, 113, 4487-4498.
73. Quintanilla-Dieck, M. J.; Codriansky, K.; Keady, M.; Bhawan, J.; Rünger, T. M. Expression and regulation of cathepsin K in skin fibroblasts. Exp. Dermatol., 2009, 18, 596-602.
74. Dodds, R. A.; James, I. E.; Rieman, D.; Ahern, R.; Hwang, S. M.; Connor, J. R.; Thompson, S. D.; Veber, D. F.; Drake, F. H.; Holmes, S.; Lark, M. W.; Gowen, M. Human osteoclast cathepsin K is processed intracellularly prior to attachment and bone resorption. J. Bone Miner. Res., 2001, 16, 478-486.
75. Zhao, Q.; Jia, Y.; Xiao, Y. Cathepsin K: a therapeutic target for bone diseases. Biochem. Biophys. Res. Commun., 2009, 380, 721-723.
76. Wilson, S. R.; Peters, C.; Saftig, P.; Brömme, D. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J. Biol. Chem., 2009, 284, 2584-1592.
77. Riese, R. J.; Wolf, P. R.; Brömme, D.; Natkin, L. R.; Villadangos, J. A.; Ploegh, H. L.; Chapman, H. A. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity, 1996, 4, 357-366.
78. Villadangos, J. A.; Riese, R. J.; Peters, C.; Chapman, H. A.; Ploegh, H. L. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J. Exp. Med., 1997, 186, 549-560.
79. Nakagawa, T.; Brissette, W. H.; Lira, P. D.; Griffiths, R. J.; Petrushova, N.; Stock, J.; McNeish, J. D.; Eastman, S. E.; Howard, E. D.; Clarke, S. R. M.; Rosloniec, E. F.; Elliott, E. A.; Rudensky, A. Y. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity, 1999, 10, 207-217.
80. Honey, K.; Rudensky, A. Y. Lysosomal cysteine proteases regulate antigen presentation. Nat. Rev. Immunol., 2003, 3, 472-482.
81. Gupta, S.; Singh, R. K.; Dastidar, S.; Ray, A. Cysteine cathepsin S as an immunomodulatory target: present and future trends. Expert Opin. Ther. Targets, 2008, 12, 291-299.
82. Palmer, J. T.; Rasnick, D.; Klaus, J. L.; Brömme, D. Vinyl sulfones as mechanism-based cysteine protease inhibitors. J. Med. Chem., 1995, 38, 3193-3196.
83. Lützner, N.; Kalbacher, H. Quantifying cathepsin S activity in antigen presenting cells using a novel specific substrate. J. Biol. Chem., 2008, 283, 36185-36194.
84. Shi, G. P.; Bryant, R. A.; Riese, R.; Verhelst, S.; Driessen, C.; Li, Z.; Brömme, D.; Ploegh, H. L.; Chapman, H. A. Role of cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J. Exp. Med., 2000, 191, 1177-1186.
85. Green, E. L. The genetics of a new hair deficiency, furless. J. Hered., 1954, 45, 115-118.
86. Hook, V. Y. Protease pathways in peptide neurotransmission and neurodegenerative diseases. Cell. Mol. Neurobiol., 2006, 26, 449-469.
87. Abboud-Jarrous, G.; Atzmon, R.; Peretz, T.; Palermo, C.; Gadea, B. B.; Joyce, J. A.; Vlodavsky, I. Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment. J. Biol. Chem., 2008, 283, 18167-18176.
88. Zavašnik-Bergant, T.; Turk, B. Cysteine proteases: destruction ability versus immunomodulation capacity in immune cells. Biol. Chem., 2007, 388, 1141-1149.
89. Adkison, A. M.; Raptis, S. Z.; Kelley, D. G.; Pham, C. T. Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis. J. Clin. Invest., 2002, 109, 363-371.
90. Méthot, N.; Rubin, J.; Guay, D.; Beaulieu, C.; Ethier, D.; Reddy, T. J.; Riendeau, D.; Percival, M. D. Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing. J. Biol. Chem., 2007, 282, 20836-20846.
91. Vasiljeva, O.; Reinheckel, T.; Peters, C.; Turk, D.; Turk, V.; Turk, B. Emerging roles of cysteine cathepsins in disease and their potential as drug targets. Curr. Pharm. Des., 2007, 13, 387-403.
92. Berdowska, I. Cysteine proteases as disease markers. Clin. Chim. Acta, 2004, 342, 41-69.
93. Chang, W. S. W.; Wu, H. R.; Yeh, C. T.; Wu, C. W.; Chang, J. Y. Lysosomal cysteine proteinase cathepsin S as a potential target for anti-cancer therapy. J. Cancer Mol., 2007, 3, 5-14.
94. Gocheva, V.; Joyce, J. A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle, 2007, 6, 60-64.
95. Affara, N. I.; Andreu, P.; Coussens, L. M. Delineating protease functions during cancer development. Methods Mol. Biol., 2009, 539, 1-32.
96. Kuester, D.; Lippert, H.; Roessner, A.; Krueger, S. The cathepsin family and their role in colorectal cancer. Pathol. Res. Pract., 2008, 204, 491-500.
97. Palermo, C.; Joyce, J. A. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci., 2008, 29, 22-28.
98. Stoch, S. A.; Wagner, J. A. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin. Pharmacol. Ther., 2008, 83, 172-175.
99. Le Gall, C.; Bonnelye, E.; Clézardin, P. Cathepsin K inhibitors as treatment of bone metastasis. Curr. Opin. Support. Palliat. Care, 2008, 2, 218-222.
100. Bengtsson, E.; Nilsson, J.; Jovinge, S. Cystatin C and cathepsins in cardiovascular disease. Front. Biosci., 2008, 13, 5780-5786.
101. Yasuda, Y.; Kaleta, J.; Brömme, D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv. Drug. Deliv. Rev., 2005, 57, 973-993.
102. Saegusa, K.; Ishimaru, N.; Yanagi, K.; Arakaki, R.; Ogawa, K.; Saito, I.; Katunuma, N.; Hayashi, Y. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J. Clin. Invest., 2002, 110, 361-369.
103. Bidère, N.; Lorenzo, H. K.; Carmona, S.; Laforge, M.; Harper, F.; Dumont, C.; Senik, A. Cathepsin D triggers Bax activation, resulting in selective apoptosis-inducing factor (AIF) relocation in T lymphocytes entering the early commitment phase to apoptosis. J. Biol. Chem., 2003, 278, 31401-31411.
104. Zhang, H.; Zhong, C.; Shi, L.; Guo, Y.; Fan, Z. Granulysin induces cathepsin B release from lysosomes of target tumor cells to attack mitochondria through processing of bid leading to necroptosis. J. Immunol., 2009, 182, 6993-7000.
105. Grimm, J.; Kirsch, D. G.; Windsor, S. D.; Kim, C. F.; Santiago, P. M.; Ntziachristos, V.; Jacks, T.; Weissleder, R. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc. Natl. Acad. Sci. USA, 2005, 102, 14404-14409.
106. Cardone, R. A.; Casavola, V.; Reshkin, S. J. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat. Rev. Cancer, 2005, 5, 786-795.
107. Gelb, B. D.; Shi, G. P.; Chapman, H. A.; Desnick, R. J. Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science, 1996, 273, 1236-1238.
108. Toomes, C.; James, J.; Wood, A. J.; Wu, C. L.; McCormick, D.; Lench, N.; Hewitt, C.; Moynihan, L.; Roberts, E.; Woods, C. G.; Markham, A.; Wong, M.; Widmer, R.; Ghaffar, K. A.; Pemberton, M.; Hussein, I. R.; Temtamy, S. A.; Davies, R.; Read, A. P.; Sloan, P.; Dixon, M. J.; Thakker. N. S. Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis. Nat. Genet., 1999, 23, 421-424.
109. Pennacchio, L. A.; Lehesjoki, A. E.; Stone, N. E.; Willour, V. L.; Virtaneva, K.; Miao, J.; D'Amato, E.; Ramirez, L.; Faham, M.; Koskiniemi, M.; Warrington, J. A.; Norio, R.; de la Chapelle, A.; Cox, D. R.; Myers, R. M. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science, 1996, 271, 1731-1374.
110. Selkoe, D. J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81, 741-766.
111. Thinakaran, G.; Koo, E. H. Amyloid precursor protein trafficking, processing, and function. J. Biol. Chem., 2008, 283, 29615-29619.
112. Hook, V.; Toneff, T.; Bogyo, M.; Greenbaum, D.; Medzihradszky, K. F.; Neveu, J.; Lane, W.; Hook, G.; Reisine, T. Inhibition of cathepsin B reduces beta-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate β-secretase of Alzheimer's disease. Biol. Chem., 2005, 386, 931-940.
113. Mueller-Steiner, S.; Zhou, Y.; Arai, H.; Roberson, E. D.; Sun, B.; Chen, J.; Wang, X.; Yu, G.; Esposito, L.; Mucke, L.; Gan, L. Antiamyloidogenic and neuroprotective Functions of Cathepsin B: implications for Alzheimer's disease. Neuron, 2006, 51, 703-714.
114. Hook, V.; Kindy, M.; Hook, G. Cysteine protease inhibitors effectively reduce in vivo levels of brain beta-amyloid related to Alzheimer's disease. Biol. Chem., 2007, 388, 247-252.
115. Hook, V. Y.; Kindy, M.; Hook, G. Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedish mutant, β-secretase site of the amyloid precursor protein. J. Biol. Chem., 2008, 283, 7745-7753.
116. Hook, V. Y.; Kindy, M.; Reinheckel, T.; Peters, C.; Hook, G. Genetic cathepsin B deficiency reduces β-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem. Biophys. Res. Commun., 2009, 386, 284-288.
117. Klein, D. M.; Felsenstein, K. M.; Brenneman, D. E. Cathepsins B and L differentially regulate amyloid precursor protein processing. J. Pharmacol. Exp. Ther., 2009, 328, 813-821.
118. Kawase, M.; Shirato, K.; Matsuyama, S.; Taguchi, F. Protease-mediated entry via the endosome of human coronavirus 229E. J. Virol., 2009, 83, 712-721.
119. Chandran, K.; Sullivan, N. J.; Felbor, U.; Whelan, S. P.; Cunningham, J. M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science, 2005, 308, 1643-1645.
120. Schornberg, K.; Matsuyama, S.; Kabsch, K.; Delos, S.; Bouton, A.; White, J. Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. J. Virol., 2006, 80, 4174-4178.
121. MacIntyre, A. C.; Cutler, D. J. The potential role of lysosomes in tissue distribution of weak bases. Biopharm. Drug Dispos., 1988, 9, 513-526.
122. Falgueyret, J. P.; Desmarais, S.; Oballa, R.; Black, W. C.; Cromlish, W.; Khougaz, K.; Lamontagne, S.; Massé, F.; Riendeau, D.; Toulmond, S.; Percival, M. D. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J. Med. Chem., 2005, 48, 7535-7543.
123. Falgueyret, J. P.; Black, W. C.; Cromlish, W.; Desmarais, S., Lamontagne, S.; Mellon, C., Riendeau, D.; Rodan, S.; Tawa, P., Wesolowski, G.; Bass, K. E.; Venkatraman, S.; Percival, M. D. An activity-based probe for the determination of cysteine cathepsin protease activities in whole cells. Anal. Biochem. 2004, 335, 218-227.
124. Desmarais, S.; Massé, F.; Percival, M. D. Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools. Biol. Chem., 2009, 390, 941-948.
125. Black, W. C.; Percival, M. D. The consequences of lysosomotropism on the design of selective cathepsin K inhibitors. ChemBioChem, 2006, 7, 1525-1535.
126. Desmarais, S.; Black, W. C.; Oballa, R.; Lamontagne, S.; Riendeau, D.; Tawa, P.; Duong le, T.; Pickarski, M.; Percival, M. D. Effect of cathepsin k inhibitor basicity on in vivo off-target activities. Mol. Pharmacol., 2008, 73, 147-156.
127. Naisbitt, D. J.; Gordon, S. F.; Pirmohamed, M.; Park, B. K. Immunological principles of adverse drug reactions: the initiation and propagation of immune responses elicited by drug treatment. Drug Saf., 2000, 23, 483-507.
128. Evans, D. C.; Watt, A. P.; Nicoll-Griffith, D. A.; Baillie T. A. Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol., 2004, 17, 3-16.
129. Potashman, M. H.; Duggan, M. E. Covalent modifiers: an orthogonal approach to drug design. J. Med. Chem., 2009, 52, 1231-1246.
130. Engel, J. C.; Doyle, P. S.; Hsieh, I.; McKerrow, J. H. Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med., 1998, 188, 725-734.
131. Powers, J. C.; Asgian, J. L.; Ekici, Ö. D.; James, K. E. Irreversible inhibitors of serine, cysteine and threonine proteases. Chem. Rev., 2002, 102, 4639-4750.
132. Richardson; P. G.; Mitsiades, C.; Hideshima, T.; Anderson, K. C. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu. Rev. Med., 2006, 57, 33-47.
133. Leung-Toung, R.; Li, W.; Tam, T. F.; Karimian, K. Thiol-dependent enzymes and their inhibitors: a review. Curr. Med. Chem., 2002, 9, 979-1002.
134. Reesink, H. W.; Zeuzem, S.; Weegink, C. J.; Forestier, N.; van Vliet, A.; van de Wetering de Rooij, J.; McNair, L.; Purdy, S.; Kauffman, R.; Alam, J.; Jansen, P. L. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology, 2006, 131, 997-1002.
135. Stoch, S. A.; Zajic, S.; Stone, J.; Miller, D. L.; Van Dyck, K.; Gutierrez, M. J.; De Decker, M.; Liu, L.; Liu, Q.; Scott, B. B.; Panebianco, D.; Jin, B.; Duong, L. T.; Gottesdiener, K.; Wagner, J. A. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin. Pharmacol. Ther., 2009, 86, 175-182.
136. Santos, M. M.; Moreira, R. Michael acceptors as cysteine protease inhibitors. Mini Rev. Med. Chem., 2007, 7, 1040-1050.
137. Schirmeister, T., Kaeppler, U. Non-peptidic inhibitors of cysteine proteases. Min. Rev. Med. Chem., 2003, 3, 361-373.
138. Schirmeister, T., Klockow, A. Cysteine protease inhibitors containing small rings. Min. Rev. Med. Chem., 2003, 3, 585-596.
139. Vicik, R.; Busemann, M.; Baumann, K.; Schirmeister, T. Inhibitors of cysteine proteases. Curr. Top. Med. Chem., 2006, 6, 331-353.
140. Hernandez, A. A., Roush, W. R. Recent advances in the synthesis, design and selection of cysteine protease inhibitors. Curr. Opin. Chem. Biol., 2002, 6, 459-465.
141. Veber, D. F.; Thompson, S. K. The therapeutic potential of advances in cysteine inhibitor design. Curr. Opin. Drug Discov. Devel., 2000, 3, 362-369.
142. Otto, H.-H.; Schirmeister, T. Cysteine proteases and their inhibitors. Chem. Rev., 1997, 97, 133-171.
143. Lecaille, F.; Kaleta, J.; Brömme, D. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev., 2002, 102, 4459-4488.
144. Brömme, D.; Kaleta, J. Thiol-dependent cathepsins: pathophysiological implications and recent advances in inhibitor design. Curr. Pharm. Des., 2002, 8, 1639-1658.
145. Grabowska, U. B.; Chambers, T. J.; Shiroo, M. Recent developments in cathepsin K inhibitor design. Curr. Opin. Drug Discov. Devel., 2005, 8, 619-630.
146. Deaton, D. N.; Tavares, F. X. Design of cathepsin K inhibitors for osteoporosis. Curr. Top. Med. Chem., 2005, 5, 1639-1675.
147. Sani, M.; Volonterio, A.; Zanda, M. The trifluoroethylamine function as peptide bond replacement. ChemMedChem, 2007, 2, 1693-1700.
148. Leung-Toung, R.; Zhao, J.; Li, W.; Tam, T. F.; Karimian, K. Thiol proteases: inhibitors and potential therapeutic targets. Curr. Med. Chem., 2006, 13, 547-581.
149. Lucas, E. C.; Williams, A. The pH dependencies of individual rate constants in papain-catalyzed reactions. Biochemistry, 1969, 8, 5125-5135.
150. Lewis, C. A. Jr.; Wolfenden R. Thiohemiacetal formation by inhibitory aldehydes at the active site of papain. Biochemistry, 1977, 16, 4890-4895.
151. Thompson, S. A.; Andrews, P. R.; Hanzlik, R. P. Carboxyl-modified amino acids and peptides as protease inhibitors. J. Med. Chem., 1986, 29, 104-111.
152. Moon, J. B.; Coleman, R. S.; Hanzlik, R. P. Reversible covalent inhibition of papain by a peptide nitrile. 13C-NMR evidence for a thioimidate ester adduct. J. Am. Chem. Soc., 1986, 108, 1350-1351.
153. Liang, T. C.; Abeles, R. H.; Inhibition of papain by nitriles: mechanistic studies using NMR and kinetic measurements. Arch. Biochem. Biophys., 1987, 252, 626-634.
154. Brisson, J.-R.; Carey, P. R.; Storer, A. C. Benzoylamidoacetonitrile is bound as a thioimidate in the active site of papain. J. Biol. Chem., 1986, 261, 9087-9089.
155. Gütschow, M.; Powers, J. C. 2-Alkylthio-4-oxo-3- quinazolineacetonitriles and analogous thieno[3,2-d] pyrimidineacetonitriles: reaction with thiols via trapped thioimidates. J. Org. Chem., 2001, 66, 4723-4727.
156. Hanzlik, R. P.; Jacober, S. P.; Zygmunt, J. Reversible binding of peptide aldehydes to papain. Structure-activity relationships. Biochim. Biophys. Acta, 1991, 1073, 33-42.
157. Dufour, É.; Storer, A. C.; Ménard, R. Peptide aldehydes and nitriles as transition state analog inhibitors of cysteine proteases. Biochemistry, 1995, 34, 9136-9143.
158. Kim, J. B.; Kopcho, L. M.; Kirby, M. S.; Hamann, L. G.; Weigelt, C. A.; Metzler, W. J.; Marcinkeviciene, J. Mechanism of Gly-PropNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118). Arch. Biochem. Biophys., 2006, 445, 9-18.
159. Ho, T.-L. The hard soft acids bases (HSAB) principle and organic chemistry. Chem. Rev., 1975, 75, 2-20.
160. Ho, T.-L.; Ho, H. C.; Hamilton, L. D. Biochemical significance of the hard and soft acids ad bases principle. Chem. Biol. Interact., 1978, 23, 65-84.
161. Thornberry, N. A.; Weber, A. E. Discovery of JANUVIA (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Curr. Top. Med. Chem., 2007, 7, 557-568.
162. Brandt, I.; Joossens, J.; Chen, X.; Maes, M.-B.; Scharpé, S.; De Meester, I.; Lambeir, A.-M. Inhibition of dipeptidyl-peptidase IV catalyzed peptide truncation by Vildagliptin ((2S)-{[(3-hydroxyadamantan-1-yl)amino] acetyl}-pyrrolidine-2-carbonitrile). Biochem. Pharmacol., 2005, 70, 134-143.
163. Metzler, W. J.; Yanchunas, J.; Weigelt, C.; Kish, K.; Klei, H. E.; Xie, D.; Zhang, Y.; Corbett, M.; Tamura, J. K.; He, B.; Hamann, L. G.; Kirby, M. S.; Marcinkeviciene, J. Involvement of DPP-IV catalytic residues in enzyme-saxagliptin complex formation. Protein Sci., 2008, 17, 240-250.
164. Hanzlik, R. P.; Zygmunt J.; Moon, J. B. Reversible covalent binding of peptide nitriles to papain. Biochim. Biophys. Acta, 1990, 1035, 62-70.
165. Dufour, É.; Storer, A. C.; Ménard, R. Engineering nitrile hydratase activity into a cysteine protease by a single mutation. Biochemistry, 1995, 34, 16382-16388.
166. Versari, A.; Ménard, R.; Lortie, R. Enzymatic hydrolysis of nitriles by an engineered nitrile hydratase (papain Gln19Glu) in aqueous-organic media. Biotechnol. Bioeng., 2002, 79, 9-14.
167. Reddy, S. Y.; Kahn, K.; Zheng, Y. J.; Bruice, T. C. Protein engineering of nitrile hydratase activity of papain: molecular dynamics study of a mutant and wild-type enzyme. J. Am. Chem. Soc., 2002, 124, 12979-12990.
168. Gour-Salin, B. J.; Storer, A. C.; Castelhano, A.; Krantz, A.; Robinson, V. Inhibition of papain by peptide nitriles: reactions of external nucleophiles with the thioimidate ester adduct. Enzyme Microb. Technol., 1991, 13, 408-411.
169. Robichaud, J.; Oballa, R.; Prasit, P.; Falgueyret, J. P.; Percival, M. D.; Wesolowski, G.; Rodan, S. B.; Kimmel, D.; Johnson, C.; Bryant, C.; Venkatraman, S.; Setti, E.; Mendonca, R.; Palmer, J. T. A novel class of nonpeptidic biaryl inhibitors of human cathepsin K. J. Med. Chem., 2003, 46, 3709-3727.
170. Deaton, D. N.; Hassell, A. M.; McFadyen, R. B.; Miller, A. B.; Miller, L. R.; Shewchuk, L. M.; Tavares, F. X.; Willard, D. H.; Wright, L. L. Novel and potent cyclic cyanamide-based cathepsin K inhibitors. Bioorg. Med. Chem. Lett., 2005, 15, 1815-1819.
171. Altmann, E.; Cowan-Jacob, S. W.; Missbach, M. Novel purine nitrile derived inhibitors of the cysteine protease cathepsin K. J. Med. Chem., 2004, 47, 5833-5836.
172. Oballa, R. M.; Truchon, J. F.; Bayly, C. I.; Chauret, N.; Day, S.; Crane, S.; Berthelette, C. A. generally applicable method for assessing the electrophilicity and reactivity of diverse nitrile-containing compounds. Bioorg. Med. Chem. Lett., 2007, 17, 998-1002.
173. MacFaul, P. A.; Morley, A. D.; Crawford, J. J. A simple in vitro assay for assessing the reactivity of nitrile containing compounds. Bioorg. Med. Chem. Lett., 2009, 19, 1136-1138.
174. Myers, M. C.; Napper, A. D.; Motlekar, N.; Shah, P. P.; Chiu, C.-H.; Beavers, M. P.; Diamond, S. L.; Huryna, D. M.; Smith, A. B. III, Identification and characterization of 3-substituted pyrazolyl esters as alternate substrates for cathepsin B: the confounding effects of DTT and cysteine in biological assays. Bioorg. Med. Chem. Lett., 2007, 17, 4761-4766.
175. Greenspan, P. D.; Clark, K. L.; Tommasi, R. A.; Cowen, S. D.; Mcquire, L.W.; Farley, D. L.; van Duzer, J. H.; Goldberg, R. L.; Zhou, H.; Du, Z.; Fitt, J. J.; Coppa, D. E.; Fang, Z.; Macchia, W.; Zhu, L.; Capparelli, M. P.; Goldstein, R.; Wigg, A. M.; Doughty, J. R.; Bohacek, R.S.; Knap, A. K. Identification of dipeptidyl nitriles as potent and selective inhibitors of cathepsin B through structure-based drug design, J. Med. Chem., 2001, 44, 4524-4534.
176. Picken, P. P.; Guthrie, D. J. S.; Walker, B. Inhibition of bovine cathepsin B by amino acid-derived nitriles. Biochem. Soc. Trans., 1990, 18, 316.
177. Shaw, E.; Wilkstrom, P.; Ruscica, J. An exploration of the primary specificity site of cathepsin B. Arch. Biochem. Biophys., 1983, 222, 424-429.
178. Greenspan, P. D.; Clark, K. L.; Cowen, S. D.; McQuire, L. W.; Tommasi, R. A.; Farley, D. L.; Quadros, E.; Coppa, D. E.; Du, Z.; Fang, Z.; Zhou, H.; Doughty, J.; Toscano, K. T.; Wigg, A. M.; Zhou, S. N-Arylaminonitriles as bioavailable peptidomimetic inhibitors of cathepsin B. Bioorg. Med. Chem. Lett., 2003, 13, 4121-4124.
179. Ward, Y. D.; Thomson, D. S.; Frye, L. L.; Cywin, C. L.; Morwick, T.; Emmanuel, M. J.: Zindell, R.; McNeil, D.; Bekkali, Y.; Giradot, M.: Hrapchak, M.; DeTuri, M.; Crane, K.; White, D.; Pav, S.; Wang, Y.; Hao, M. H.; Grygon, C. A.; Labadia, M. E.; Freeman, D. M.; Davidson, W.; Hopkins, J. L.; Brown, M. L.; Spero, D. M. Design and synthesis of dipeptide nitriles as reversible and potent cathepsin S inhibitors. J. Med. Chem., 2002, 45, 5471-5482.
180. Löser, R.; Schilling, K.; Dimmig, E.; Gütschow, M. Interaction of papain-like cysteine proteases with dipeptide-derived nitriles. J. Med. Chem., 2005, 48, 7688-7707.
181. Rüttger, A.; Mollenhauer, J.; Löser, R.; Gütschow, M.; Wiederanders, B. Microplate assay for quantitative determination of cathepsin activities in viable cells using derivatives of 4-methoxy-beta-naphthylamide. Biotechniques, 2006, 41, 469-473.
182. Ruettger, A.; Schueler, S.; Mollenhauer, J. A.; Wiederanders, B. Cathepsins B, K, and L are regulated by a defined collagen type II peptide via activation of classical protein kinase C and p38 MAP kinase in articular chondrocytes. J. Biol. Chem., 2008, 283, 1043-1051.
183. Patterson, A. W.; Wood, W. J.; Hornsby, M.; Lesley, S.; Spraggon, G.; Ellman, J. A. Identification of selective, nonpeptidic nitrile inhibitors of cathepsin S using the substrate activity screening method. J. Med. Chem., 2006, 49, 6298-6307.
184. Wood, W. J. L.; Patterson, A. W.; Tsuruoka, H.; Jain, R. K.; Ellman, J. A. Substrate activity screening: a fragment-based method for the rapid identification of nonpeptidic protease inhibitors. J. Am. Chem. Soc., 2005, 127, 15521-15527.
185. Gauthier, J. Y.; Black, W. C.; Courchesne, I.; Cromlish, W.; Desmarais, S.; Houle, R.; Lamontagne, S.; Li C. S.; Massé, F.; McKay, D. J.; Ouellet, M.; Robichaud, J.; Truchon, J. F.; Truong, V. L.; Wang, Q.; Percival, M. D. The identification of potent, selective, and bioavailable cathepsin S inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 4929-4933.
186. Bethel, P. A.; Gerhardt, S.; Jones, E. V.; Kenny, P. W.; Karoutchi, G. I.; Morley, A. D.; Oldham, K.; Rankine, N.; Augustin, M.; Krapp, S.; Simader, H.; Steinbacher, S. Design of selective cathepsin inhibitors. Bioorg. Med. Chem. Lett., 2009, 19, 4622-4625.
187. Asaad, N.; Bethel, P. A.; Coulson, M. D.; Dawson, J. E.; Ford, S. J.; Gerhardt, S.; Grist, M.; Hamlin, G. A.; James, M. J.; Jones, E. V.; Karoutchi, G. I.; Kenny, P. W.; Morley, A. D.; Oldham, K.; Rankine, N.; Ryan, D.; Wells, S. L.; Wood, L.; Augustin, M.; Krapp, S.; Simader, H.; Steinbacher, S. Dipeptidyl nitrile inhibitors of cathepsin L. Bioorg. Med. Chem. Lett., 2009, 19, 4280-4283.
188. Löser, R.; Frizler, M.; Schilling, K.; Gütschow, M. Azadipeptide nitriles: highly potent and proteolytically stable inhibitors of papain-like cysteine proteases. Angew. Chem. Int. Ed., 2008, 47, 4331-4334.
189. Bondebjerg, J.; Fuglsang, H.; Valeur, K. R.; Pedersen, J.; Naerum, L. Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 3614-3617.
190. Méthot, N.; Guay, D.; Rubin, J.; Ethier, D.; Ortega, K.; Wong, S.; Normandin, D.; Beaulieu, C.; Reddy, T. J.; Riendeau, D.; Percival, M. D. In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C. Mol. Pharmacol., 2008, 73, 1857-1865.
191. Guay, D.; Beaulieu, C.; Reddy, T. J.; Zamboni, R.; Méthot, N.; Rubin, J.; Ethier, D.; Percival, M. D. Design and synthesis of dipeptidyl nitriles as potent, selective, and reversible inhibitors of cathepin C. Bioorg. Med. Chem. Lett., 2009, 19, 5392-5396.
192. Falgueyret, J. P.; Oballa, R. M.; Okamoto, O.; Wesolowski, G.; Aubin, Y.; Rydzewski, R. M.; Prasit, P.; Riendeau, D.; Rodan, S. B.; Percival, M. D. Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L. J. Med. Chem., 2001, 44, 94-104.
193. Rydzewski, R. M.; Bryant, C.; Oballa, R.; Wesolowski, G.; Rodan, S. B.; Bass, K. E.; Wong, D. H. Peptidic 1-cyanopyrrolidines: synthesis and SAR of a series of potent, selective cathepsin inhibitors. Bioorg. Med. Chem., 2002, 10, 3277-3284.
194. Barrett, D. G.; Deaton, D. N.; Hassell, A. M.; McFadyen, R. B.; Miller, A. B.; Miller, L. R.; Payne, J. A.; Shewchuk, L. M.; Willard, D. H.; Wright, L. L. Acyclic cyanamide-based inhibitors of cathepsin K. Bioorg. Med. Chem. Lett., 2005, 15, 3039-3043.
195. Robichaud, J.; Bayly, C.; Oballa, R.; Prasit, P.; Mellon, C.; Falgueyret, J. P.; Percival, M. D.; Wesolowski, G.; Rodan, S. B. Rational design of potent and selective NH-linked aryl/heteroaryl cathepsin K inhibitors. Bioorg. Med. Chem. Lett., 2004, 14, 4291-4295.
196. Palmer, J. T.; Bryant, C.; Wang, D. X.; Davis, D. E.; Setti, E. L.; Rydzewski, R. M.; Venkatraman, S.; Tian, Z. Q.; Burrill, L. C.; Mendonca, R. V.; Springman, E.; McCarter, J.; Chung, T.; Cheung, H.; Janc, J. W.; McGrath, M.; Somoza, J. R.; Enriquez, P.; Yu, Z. W.; Strickley, R. M.; Liu, L.; Venuti, M. C.; Percival, M. D.; Falgueyret, J. P.; Prasit, P.; Oballa, R.; Riendeau, D.; Young, R. N.; Wesolowski, G.; Rodan, S. B.; Johnson, C.; Kimmel, D. B.; Rodan, G. Design and synthesis of tri-ring P3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J. Med. Chem., 2005, 48, 7520-7534.
197. Crane, S. N.; Black, W. C.; Palmer, J. T.; Davis, D. E.; Setti, E.; Robichaud, J.; Paquet, J.; Oballa, R. M.; Bayly, C. I.; McKay, D. J.; Somoza, J. R.; Chauret, N.; Seto, C.; Scheigetz, J.; Wesolowski, G.; Masse, F.; Desmarais, S.; Ouellet, M. Beta-substituted cyclohexanecarboxamide: a nonpeptidic framework for the design of potent inhibitors of cathepsin K. J. Med. Chem., 2006, 49, 1066-1079.
198. Robichaud, J.; Black, W. C.; Thérien, M.; Paquet, J.; Oballa, R. M.; Bayly, C. I.; McKay, D. J.; Wang, Q.; Isabel, E.; Léger, S.; Mellon, C.; Kimmel, D. B.; Wesolowski, G.; Percival, M. D.; Massé, F.; Desmarais, S.; Falgueyret, J. P.; Crane, S. N. Identification of a nonbasic, nitrile-containing cathepsin K inhibitor (MK-1256) that is efficacious in a monkey model of osteoporosis. J. Med. Chem., 2008, 51, 6410-6420.
199. Gauthier, J. Y.; Chauret, N.; Cromlish, W.; Desmarais, S.; Duong le, T:, Falgueyret, J. P.; Kimmel, D. B.; Lamontagne, S.; Léger, S.; LeRiche, T.; Li, C. S.; Massé, F.; McKay, D. J.; Nicoll-Griffith, D. A.; Oballa, R. M.; Palmer, J. T.; Percival, M. D.; Riendeau, D.; Robichaud, J.; Rodan, G. A.; Rodan, S. B.; Seto, C.; Thérien, M.; Truong, V. L.; Venuti, M. C.; Wesolowski, G.; Young, R. N.; Zamboni, R.; Black, W. C. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg. Med. Chem. Lett., 2008, 18, 923-928.
200. Molecular Operating Environment (MOE), Chemical Computing Group, Montreal, Canada. 2007.